These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2628 related articles for article (PubMed ID: 26136504)

  • 1. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
    Yan Y; Zuo X; Wei D
    Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of CD44 and Cancer Stem Cells.
    Wang L; Zuo X; Xie K; Wei D
    Methods Mol Biol; 2018; 1692():31-42. PubMed ID: 28986884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of alternative splicing of CD44 in cancer.
    Prochazka L; Tesarik R; Turanek J
    Cell Signal; 2014 Oct; 26(10):2234-9. PubMed ID: 25025570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
    Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
    Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.
    Bourguignon LYW; Earle C; Shiina M
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44 is a multidomain signaling platform that integrates extracellular matrix cues with growth factor and cytokine signals.
    Orian-Rousseau V; Sleeman J
    Adv Cancer Res; 2014; 123():231-54. PubMed ID: 25081532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knock out CD44 in reprogrammed liver cancer cell C3A increases CSCs stemness and promotes differentiation.
    Han S; Guo J; Liu Y; Zhang Z; He Q; Li P; Zhang M; Sun H; Li R; Li Y; Zeng W; Liu J; Lian L; Gao Y; Shen L
    Oncotarget; 2015 Dec; 6(42):44452-65. PubMed ID: 26540347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cells (CSCs) in cancer progression and therapy.
    Najafi M; Farhood B; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer.
    Karousou E; Misra S; Ghatak S; Dobra K; Götte M; Vigetti D; Passi A; Karamanos NK; Skandalis SS
    Matrix Biol; 2017 May; 59():3-22. PubMed ID: 27746219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redox regulation in stem-like cancer cells by CD44 variant isoforms.
    Nagano O; Okazaki S; Saya H
    Oncogene; 2013 Oct; 32(44):5191-8. PubMed ID: 23334333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CD44v
    Hu J; Li G; Zhang P; Zhuang X; Hu G
    Cell Death Dis; 2017 Mar; 8(3):e2679. PubMed ID: 28300837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sasa quelpaertensis Leaf Extract Inhibits Colon Cancer by Regulating Cancer Cell Stemness in Vitro and in Vivo.
    Min SJ; Lim JY; Kim HR; Kim SJ; Kim Y
    Int J Mol Sci; 2015 Apr; 16(5):9976-97. PubMed ID: 25941936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bad seed: Cancer stem cells in tumor development and resistance.
    Koren E; Fuchs Y
    Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer stem cells: the promise and the potential.
    Ajani JA; Song S; Hochster HS; Steinberg IB
    Semin Oncol; 2015 Apr; 42 Suppl 1():S3-17. PubMed ID: 25839664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells.
    Lau WM; Teng E; Chong HS; Lopez KA; Tay AY; Salto-Tellez M; Shabbir A; So JB; Chan SL
    Cancer Res; 2014 May; 74(9):2630-41. PubMed ID: 24618343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
    Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
    Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.
    Yun EJ; Zhou J; Lin CJ; Hernandez E; Fazli L; Gleave M; Hsieh JT
    Clin Cancer Res; 2016 Feb; 22(3):670-9. PubMed ID: 26490309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.
    Ranji P; Salmani Kesejini T; Saeedikhoo S; Alizadeh AM
    Tumour Biol; 2016 Oct; 37(10):13059-13075. PubMed ID: 27561758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling.
    Zeilstra J; Joosten SP; van Andel H; Tolg C; Berns A; Snoek M; van de Wetering M; Spaargaren M; Clevers H; Pals ST
    Oncogene; 2014 Jan; 33(5):665-70. PubMed ID: 23318432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 132.